Results 91 to 100 of about 26,691 (223)

A Catalogue of Dispensation Lengths for Building Treatment Episodes—Application of the Waiting Time Distribution to All Commonly Prescribed Drugs in Denmark

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
ABSTRACT Background In pharmacoepidemiologic research, correct assignment of the length of single dispensation is critical to build treatment episodes. The parametric reverse waiting time distribution (rWTD) is a particularly attractive data‐driven method to estimate dispensation lengths.
Mette Reilev, Lotte Rasmussen, Jonas Kanstrup Olsen, Martin Thomsen Ernst, Saad Hanif Abbasi, Rikke Wesselhoeft, Mette Bliddal, Jesper Hallas, Henrik Støvring   +8 more
wiley   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1489-1498, September 2026.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

Tackling aging and chronic disease: How space exploration and the ‘chameleon effect’ of pharmaceuticals can lead the way

Experimental Physiology, Volume 111, Issue 9, Page 4064-4072, 1 September 2026.
Abstract A common misconception surrounding space exploration is that humanity's pursuit of interplanetary travel, such as missions to Mars, is an escape from Earth. In reality, this endeavour offers an invaluable opportunity to address critical biomedical challenges here at home.
Carina Kern, Tina Woods, Keith Siew
wiley   +1 more source

DIHYDROPYRIDINE CALCIUM ANTAGONISTS: DATA OF EVIDENCE BASED MEDICINE AND RECOM-MENDATIONS ON PRACTICAL USE

Рациональная фармакотерапия в кардиологии, 2015
The classification of calcium antagonists is presented. There were considered the results of large randomized trials, which were devoted to study of influence of dihydropyridine calcium antagonists on the risk of cardiovascular complications.
S. Y. Martsevich
doaj   +1 more source

Dimethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

, 2009
In the crystal of the title compound, C11H15NO4, the molecules are linked into sheets by N—H...O and C—H...O hydrogen bonds.
Dong Xian, Jiange Wang, Zhenfeng Zhang, Guisheng Zhang, Zhenfeng Zhang   +4 more
core   +1 more source

Diethyl 4-(1H-indol-3-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

IUCrData, 2019
In the title compound, C21H24N2O4, the 1,4-dihydropyridine ring adopts a very flattened boat conformation, with the 3-pyridine substituent in an axial orientation.
Ji Hye Lee, Dongsoo Koh
doaj   +1 more source

Density, Sound Speed, and Viscosity of Dihydropyridine Derivatives in Dimethyl Sulfoxide at Different Temperatures

, 2016
Some novel dihydropyridine derivatives, viz., 4-(4-hydroxy-3-methoxyphenyl)-6-(2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, 4-(4-hydroxy-3-methoxyphenyl)-6-(4-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, 6-(4-chlorophenyl)-4-(4 ...
Rahul M. Talaviya (2544049), Shipra Baluja (2403676)   +1 more
core   +1 more source

Perioperative Acute Hypertension – Role of Clevidipine Butyrate

Frontiers in Pharmacology, 2014
Lakshmi N Kurnutala, Suren eSoghomonyan, Sergio Daniel Bergese, Sergio Daniel Bergese   +3 more
doaj   +1 more source

PartI. Study of 1-Acyl-2-dimethylphenylsilyl-2,3-dihydro-4-pyridone as Synthetic Intermediates. Part II. Synthesis of Nicotine Derivatives from Nicotine.

, 2005
Various methodologies were investigated to build synthetic intermediates from 1-acyl-2-dimethylphenylsilyl-2,3-dihydro-4-pyridones and to synthesize nicotine derivatives from nicotine.
Smith, Emilie Despagnet
core